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During mammal pregnancy, a sensitive balance between hormones, cytokines, humoral factors, and local cellular interactions
must be established. Cytotoxic cells infiltrating the decidua are heavily equipped with cytolytic molecules, in particular perforin
and granulysin. Granulysin is especially abundant in NK cells which are able to spontaneously secrete high quantities of
granulysin. Besides being a potent bactericidal and tumoricidal molecule, granulysin is also found to be a chemoattractant and
a proinflammatory molecule. The precise role(s) of granulysin at the maternal-fetal interface has not been elucidated yet. It is
possible that it behaves as a double-edged sword simultaneously acting as an immunomodulatory and a host defense molecule
protecting both the mother and the fetus from a wide spectrum of pathogens, and on the other hand, in case of an NK cell
activation, acting as an eﬀector molecule causing the apoptosis of semiallograft trophoblast cells and consequently leading to
various pregnancy disorders or pregnancy loss.
1. Introduction
Pregnancy is a unique event whereby the fetal semiallogenic
trophoblast cells develop a close contact with the mother’s
fully competent immune system. In order for implantation to
be successful, the uterus must undergo specific tissue trans-
formation to establish a sensitive cytokine and hormonal
balance [1]. Decidualization of the human endometrium
following embryo implantation is normally associated with
massive recruitment of distinct CD56brightCD16− natural
killer (NK) cells [2, 3]. Sharing common cytotoxic pathways
with cytotoxic T lymphocytes (CTL), these cells collectively
play a vital role in the maintenance of pregnancy and
protection against numerous pathogens. There are two
main pathways of lymphocyte-mediated cytotoxicity: (i)
granule exocytosis pathway and (ii) death receptor signaling
pathways [4, 5].
2. Granule Exocytosis Pathway
The granule exocytosis pathway is mediated via release of
cytotoxic granules directly into the synapse between the
eﬀector and their target cells. The granules released contain
a pore-forming protein, perforin, an apoptotic/cytolytic
protein, granulysin, and a family of serine proteases,
granzymes [5–7]. Upon release, perforin inserts itself into
the plasma membrane of the target cells, polymerises, and
subsequently forms cylindrical pores to allow granzymes,
in particular granzyme B, and granulysin to enter the cell
and initiate apoptosis [7]. Perforin is essential for the release
of granzymes from the cytolytic granules although, as for
granulysin, perforin is not necessary for their entry into the
target cell [8, 9] (Figure 1-I(A)).
The cytolytic machinery of decidual lymphocytes is
optimally primed to kill, but at the same time, it is precisely
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Figure 1: Cytolytic and apoptotic pathways at the maternal-fetal interface employed by cytotoxic cells and mechanisms of regulation with
the particular insight to the role(s) played by granulysin.
regulated by humoral factors, cytokines (predominantly
Th2 over Th1 cytokines), and local cellular interactions,
to prevent accidental activation that could lead to the
termination of pregnancy [10, 11]. More than 90% of all
decidual CD56brightCD16− cells express perforin, which is
present here in higher levels than in any other tissue under
physiological or pathological conditions [12]. Nonstimulated
decidual NK cells are not cytotoxic, but following an
in vitro stimulation with Th1 cytokine interleukin (IL)-2
which is in early pregnancy decidua virtually absent, they
acquire lymphokine-activated killing (LAK) activity against
trophoblast cells [13, 14]. Earlier results from our laboratory
support these findings, showing that IL-2 increases perforin
gene and protein expression in decidual lymphocytes [4].
Cytolytic activity of decidual lymphocytes is also upregulated
by IL-15, IL-18, and IL-12, all acting by increasing perforin
and FasL expression [4, 15–17] (Figure 1-I(A), (B)).
Conversely, perforin expression in decidual lymphocytes
is downregulated by progesteron, either directly or via
progesterone-induced blocking factor (PIBF) [10, 18]. The
lack of cytolytic activity of decidual NK cells against tro-
phoblasts could also be attributed to inhibitory interactions
of nonclassical class I HLA molecules (HLA-G and HLA-E)
and low polymorphic classical class I HLA molecule HLA-C
expressed by extravillous trophoblast cells with their respec-
tive inhibitory receptors immunoglobulin-like transcript 2
(ILT2), C-type lectin family receptor CD94/NKG2A, and
killer Ig-like receptors (KIRs) expressed on NK cell surface
[19–21]. In normal early pregnancy, specific interaction
between NKG2A and HLA-E mediates a dominant negative
signal in vivo, to prevent perforin recruitment and potentially
harmful cytotoxicity [22]. However, decidual NK cells also
express a series of activating receptors, such as NKG2D, but
also natural killer cytotoxicity receptors NKp30, NKp44, and
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NKp46, whose overengagement could trigger decidual NK
cell cytotoxic activity [22–24].
3. Death Receptor Pathway
The death receptor pathway is mediated by Fas/FasL, tumor
necrosis factor, (TNF-) receptor family, and TNF-related
apoptosis-inducing ligand (TRAIL). Fas receptor is ubiq-
uitously expressed within most healthy cells, including NK
cells, activated T and B lymphocytes, and dendritic cells
[25, 26]. FasL is in human pregnant uterus stored in the
intracellular granules of T and NK cells, localized to the
sites of close contact with the placental tissue, and can be
exocytosed upon nonspecific activation of these cells [27, 28]
(Figure 1-I(C)). The ligation of Fas and FasL results in a
classical caspase-dependent apoptosis involving the adaptor
molecule Fas-associated death domain (FADD) protein [6]
(Figure 1-I(C)). In the villous part of the placenta where the
Fas/FasL interaction seems to be involved in the regulation of
placental growth, FasL is mostly located on cytotrophoblast
cells, whereas syncytiotrophoblast cells express low FasL
levels. In contrast, interstitial trophoblast cells, which are
in close contact with the maternal leukocytes, strongly
express FasL, but not Fas. The abundant expression of FasL
on extravillous trophoblast probably serves as a defense
mechanism against activated maternal leukocytes [4, 29].
Th1 cytokines, IFN-γ and TNF-α, promote Fas expression
on trophoblast, thus making them susceptible to Fas/FasL-
mediated apoptosis by activated maternal lymphocytes,
whereas Th2 cytokines increase the resistance of trophoblast
cells to Fas-mediated apoptosis [30]. TRAIL is a TNF-protein
family member, structurally and functionally similar to FasL.
It is expressed by syncytiotrophoblast and, along with FasL,
is likely involved in the maintenance of immunoprivileged
conditions at the maternal-fetal interface [31, 32]. The exact
role of perforin and death receptor interactions during
human pregnancy has not been elucidated yet, but it is
believed that they serve as a molecular weapon of uterine NK
cells by (i) playing an important role in the acceptance of the
fetus and the control of trophoblast invasion and (ii) being
crucial for defense against microbe-infected, stressed, or
malignant cells.
4. Granulysin-Mediated Cell Death
Another protein that could be vital for the maintenance of
normal pregnancy is granulysin. Granulysin is a recently dis-
covered protein, found to be highly expressed in human NK
cells and activated CTLs. Over the last decade, granulysin has
been a protein of significant scientific interest, mainly due to
the cytolytic activity it exhibits on the numerous microbes
ranging from extracellular and intracellular bacteria to fungi
and parasites, but also due to its tumoricidal activity [9, 33].
The granulysin protein can be found in two forms: 9
and 15 kDa [34]. The cytolytic 9 kDa form is active, and
it is achieved via a posttranslational proteolytic cleavage at
the amino and carboxyl terminals of the 15 kDa precursor
granulysin protein [35]. However, Chung and colleagues [36]
have recently shown in vitro cytotoxic eﬀects even for the
15 kDa granulysin protein. Granulysin protein is expressed
in various cell subsets, such as the activated CD4+ and CD8+
T lymphocytes, NK cells and in activated, but not in resting,
CTLs [37], NKT cells [38] as well as decidual γδ T cells [39],
and tuberculosis-specific Vγ9/Vδ2 T cells [40].
Granulysin belongs to the family of saposin-like lipid
binding proteins, with the highest level of homology to NK-
lysin. The three-dimensional structure obtained from X-ray
crystallography of recombinant granulysin reveals that it is
composed of five α-helices, separated by short-loop regions
[41, 42]. It is believed that the lytic activity of granulysin can
be explained by its cationic ampholytic structure based on
which granulysin disrupts bacterial membrane which gen-
erally contains negatively charged lipids and hence mediates
bactericidal activity by osmotic shock [43, 44] (Figure 1-II),
In contrast, granulysin does not permeabilize target cell
membranes when bound to lipid rafts or phospholipid
membranes with eukaryotic lipid composition, but it can be
internalized into such cells (e.g., infected eukaryotic cells)
by lipid rafts and delivered to the early sorting endosomes
which afterwards fuse with bacteria-containing phagosomes,
where finally the lysis of bacteria is induced [45–47]. The
data on the role of perforin in granulysin uptake in infected
eukaryotic cells is inconclusive. Stenger et al. [9] reported
that in order to kill intracellular pathogens, granulysin
requires perforin as a cofactor to enter the host cells, whereas
Walch et al. [47] report that perforin promotes granulysin-
mediated bacteriolysis not by the formation of stable pores
that allow passive diﬀusion of granulysin but rather by an
increase in endosome-phagosomes fusion triggered by an
intracellular Ca2+ rise (Figure 1-II).
Death of the tumor cells is caused by granulysin-initiated
apoptosis. Upon binding to the membrane based on charges,
granulysin activates Sphingomyelinase followed by a slow
increase in ceramide concentration or induces an increase
in intracellular calcium and eﬄux of intracellular potassium
[48–50]. Both pathways are linked with fast mitochondrial
membrane damage, which is the key step in granulysin-
induced apoptosis [51, 52]. This results with release of
cytochrome C and apoptosis-inducing factor A [53] followed
by activation of caspases and endonucleases and finally the
cell death by apoptosis [49, 54] (Figure 1-I(A)). The latest
report by Saini et al. [50] shows that NK cell-delivered
granulysin and recombinant granulysin induce target cell
death through distinct pathways. Granulysin delivered by NK
cells does not cause mitochondrial damage or activates either
caspase-3 or caspase-9 in target cells, whereas recombinant 9-
kDa granulysin activates these pathways. Unlike recombinant
granulysin, NK cell-delivered granulysin causes both endo-
plasmic reticulum stress and caspase-7 activation in target
cells [50].
Recently, granulysin has been characterized as the first
lymphocyte-derived protein found to act as an alarmin,
capable of promoting antigen-presenting cell (APC) recruit-
ment and antigen-specific immune response [55]. At na-
nomolar concentrations, predominantly 15 kDa granulysin
acts as a chemoattractant for immune cells, such as mono-
cytes, NK cells, and CD4+ and CD8+ memory T-lymphocytes
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[55, 56] and has a proinflammatory eﬀect due to its ability
to activate monocytes to produce cytokines, such as IFN-
γ and TNF-α, and chemokines, such as MCP and RANTES
[56] (Figure 1-III). The latest results by Castiello et al. [57]
revealed that in vitro, 15 kDa granulysin induces immune
response, chemotaxis, and cell adhesion genes in human
peripheral blood monocytes. Further, granulysin-treated
monocytes upregulated genes involved in the activation of
pathways related to fundamental dendritic cell functions,
such as costimulation of T-cell activation and Th1 develop-
ment, for example, upregulation of genes in the IL-12 and
STAT4-dependent signaling [57].
Therefore, granulysin presents a novel cytolytic molecule
with immense biomedical and therapeutic potential [58].
Besides its ability to kill bacteria, fungi, and parasites,
granulysin can block viral replication and trigger apoptosis
in infected cells [59]. The fact that it can kill many deadly
pathogens makes granulysin, and its recombinant peptide
derivatives, an attractive target in the development of novel
classes of antibiotics, with less resistance observed for most
currently available therapies. In addition, 15 kDa granulysin
holds promise for therapeutic applications aimed at the
activation of the immune response.
5. Granulysin at the Maternal-Foetal Interface:
A Double-Edged Sword
Granulysin mRNA is expressed in human endometrium
of nonpregnant women with highest expression in the
late secretory phase of the menstrual cycle, correlating
with the increase in uterine NK cell number towards the
end of the secretory phase [60]. Granulysin expression is
most likely under the control of progesteron since the
antiprogestin treatment of secretory endometrial explants
decreased the granulysin mRNA expression [60]. Perforin
exhibits a similar pattern of expression during menstrual
cycle with massive recruitment of perforin-positive cells fol-
lowing the progestin-induced endometrial decidualization
[61]. The expression of granulysin mRNA in early pregnancy
and second trimester placentas increases further, whilst its
expression is downregulated at term (37–40 weeks) placentas
[62].
The granulysin (GNLY) gene expression in secretory
phase human endometrium was localized to uterine NK
cells scattered around the stroma and surrounding the
glandular epithelium [63]. Our recent results show that
first trimester pregnancy decidual tissue is diﬀusely infil-
trated by granulysin-positive cells which accumulate around
uterine glands and blood vessels [64, 65]. Granulysin
protein was also found in peripheral blood lymphocytes of
pregnant women but in significantly lower amounts [64].
Immunophenotipisation of first trimester pregnancy decid-
ual lymphocytes revealed that over 85% of CD56+CD3− NK
cells and 75% of CD56+CD3+ NKT cells express granulysin.
Similar to decidual, peripheral blood NK and NKT cells also
highly express granulysin. At gene level, granulysin is highly
expressed in all decidual lymphocyte subpopulations, espe-
cially in CD56+ cells. In comparison to other cytolytic medi-
ators (perforin, FasL, TRAIL), granulysin mRNA is present
in significantly higher levels in CD56+ and CD56+CD3+ cells,
but in T lymphocytes only, no diﬀerences between granulysin
and perforin mRNA levels were observed (unpublished
data, manuscript in preparation). It is known that NK
cells constitutively express high levels of granulysin, whereas
granulysin expression in T lymphocytes is inducible after
mitogen or alloantigen stimulation [66, 67]. Surprisingly,
more than half of decidual T lymphocytes (approximately
58%) express granulysin protein, whereas only few percent
of peripheral blood T lymphocytes express granulysin [64].
The striking increase of the percentage of granulysin-positive
decidual T lymphocytes suggests that these cells are locally
activated, even in the early phase of pregnancy, probably
after the contact with semiallogenic fetal cells and mature
dendritic cells. Hence, these cells could play a protective role
against diﬀerent pathogens at the maternal-fetal interface
by delivering granulysin which in turn either reduces the
viability of the extracellular or intracellular pathogens as
described previously, possibly leaving the host cell intact
[9, 45]. Moreover, Stenger et al. [9] correlated the CTLs
ability to reduce the viability of intracellular pathogens
with granulysin expression in these cells. The protective
role of granulysin was further supported by findings by
Fleming and coworkers [60] which stated that granulysin
enhances the innate immune capacity of endometrium since
women taking the oral combined hormonal contraceptive
pill or wearing a levonorgestrel intrauterine system have
a significantly lower expression of granulysin mRNA in
the late secretory phase of menstrual cycle and are more
susceptible to various infections. Granulysin was also found
to be expressed by γδ T cells of human early-pregnancy
decidua, further supporting the protective role of gran-
ulysin as an innate immunity molecule in early pregnancy
[39].
Granulysin could also have a very important immuno-
modulatory role at thematernal-fetal interface (Figure 1-III).
Recently, Tewary et al. [55] reported that both 9 kDa
and 15 kDa forms of granulysin induce the migration as
well as functional and phenotypical maturation of human
monocyte-derived dendritic cells (Mo-DC) by upregulation
of CD80, CD83, andMHC class II molecules. Also, it induces
higher production of IL-6, IL-8, IL-12, IL-10, and TNF-α by
Mo-DC and enhances their capacity to stimulate allogeneic
T-cell proliferation in vitro [55]. The 15 kDa granulysin
might also play an important role in activating the immune
system in response to pathogens by inducing monocytes to
recruit other immune cells by upregulating a wide group
of genes responsible for chemotaxis of diﬀerent immune
cells, such as neutrophils (CXCL1, CXCL3), T cells (CXCL11,
CXCL12, CCL20, and CCR7), monocytes (CCL2, CCL20),
macrophages, and dendritic cells (NRP2, SEMA3A) [57].
Cognition that granulysin acts as a chemoattractant to such
various cells types opens the question whether granulysin
produced by decidual NK cells could also mobilize invasive
trophoblast cells.
Our latest results revealed that uterine CD56+ cells
spontaneously secrete high levels of granulysin [64]. The
amounts of granulysin secreted by decidual CD56+ cells were
almost equivalent to values at which the peak migratory
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response of dendritic cells was observed in the study by
Tewary et al. [55]. In contrast, peripheral blood CD56+ cells
virtually do not secrete granulysin after 2 hrs in culture.
After 18 hrs in culture, they start secreting very low levels
of granulysin, which are well in agreement with studies by
Ogawa et al. [68] and Sakai et al. [69]. In our opinion,
considering that the female reproductive tract is potentially
exposed to wide range of pathogens, and infections of
genital tract during pregnancy may have severe consequences
such as miscarriage or preterm birth, the spontaneous
secretion of high levels of granulysin probably serves as a
mechanism of protection of both mother and fetoplacental
unit [64, 70, 71]. After being spontaneously secreted into
local environment, granulysin might be able to promptly
kill various pathogens without causing significant damage
to normal cells, whereas simultaneously through its eﬀects
on APCs and other immune cells it might participate in the
regulation of the adaptive immune response (Figures1-II and
1-III). Moreover, decidual APCs, both dendritic cells, and
macrophages, and IL-15 which is known to be produced
by APC, contribute to the maintenance of high granulysin
expression in decidual NK cells, thus providing continuous
local protection [64]. Another important role of granulysin
could be in one of key events of early pregnancy, the
angiogenesis, since Langer and coworkers demonstrated
that NKG5 protein (granulysin) secreted by decidual NK
cells and activated T lymphocytes stimulates mitogenicity
of endothelial cells and may be involved in angiogenesis
[72].
On the other hand, several studies have shown that
granulysin may be involved in diﬀerent pregnancy disorders
[69, 73]. Granulysin was previously associated with the
development of preeclampsia as a Th1 marker. Its serum
levels in preeclamptic patients were well associated with the
percentage of peripheral blood Th1 cells, Th1/Th2 ratios,
and the clinical outcome [69]. In cases of ectopic pregnancy,
granulysin-expressing cells were virtually absent in the tubal
mucosa which could explain invasiveness of trophoblast cells.
Interestingly, the uterine decidua of ectopic pregnancy was
simultaneously heavily infiltrated with granulysin-positive
cells [65].
As mentioned, during normal pregnancy, uterine NK
cells are not directed to kill trophoblast cells, but in case
of excessive Th1 response due to infection or inflammation,
these cells become hyperactivated and potentially cytotoxic
(Figure 1-I(B)) [30, 74]. Nakashima et al. [73] have shown
that granulysin contributes to apoptosis of extravillous tro-
phoblast cells in spontaneous abortions. Granulysin secreted
by CD56bright uterine NK cells was detected in the cytoplasm
and nuclei of apoptotic extravillous cytotrophoblast cells
suggesting that granulysin may be a key substance in
induction of spontaneous abortion. In vitro studies showed
that only hyperactivated, that is, IL-2 stimulated uterine NK
cells secrete granulysin which in turn actively accumulates
in nuclei of extravillous trophoblast cell line. Granulysin
entrance into trophoblast cells, as well as NK cell-mediated
killing of target tumor cells, was shown to be dependent
on perforin and cell-to-cell contact. [50, 73] (Figure 1-I(B)).
Several studies have shown that HLA-G molecule inhibits
natural killer cell-mediated cytotoxicity [75, 76]. In fact,
our latest results show that one of the mechanisms which
might prevent an excessive NK cell activation during normal
pregnancy could be HLA-G mediated. Namely, decidual NK
cells after the contact with HLA-G, transfected NK sensitive
K562 cells express and secrete significantly lower quantities
of granulysin in comparison to NK cells exposed to HLA-
C-transfected K562 cells (unpublished data, manuscript in
preparation).
In light of all that is currently known, and considering
that granulysin is abundantly expressed in early pregnancy
decidua, especially in NK cells, we hypothesize that gran-
ulysin is a novel lethal weapon of uterine NK cells acting
as a double-edged sword at the maternal-fetal interface
(Figure 1). At the same time, it acts as a host defense
molecule protecting both the mother and the fetus from a
wide spectrum of pathogens, and as an immunomodulatory
molecule by inducing chemotaxis of diﬀerent immune cells,
phenotypical and functional maturation of dendritic cells,
and by upregulating the adaptive immune response. On the
other hand, in case of NK cell activation, along with perforin,
granulysin can act as an eﬀector molecule causing the apop-
tosis of semiallograft trophoblast cells, consequently leading
to various pregnancy disorders including spontaneous preg-
nancy termination, intrauterine fetal growth retardation,
and preeclampsia. However, many details regarding the
exact mechanisms underlying the remarkable modes of
granulysin action and its physiological roles remain yet to be
elucidated.
Decidual cytotoxic cells are heavily equipped with cy-
tolytic molecules, in particular perforin and granulysin.
Specific interactions between nonclassical class I MHC
molecules expressed on extravillous trophoblast (EVT) cells
and their inhibitory and activating receptors expressed on
NK cell surface, along with antigen-presenting cells and
complex network of cytokines and hormones, contribute
to the maintenance of pregnancy. Th2 cytokines (IL-4, IL-
10), which are predominant in early pregnancy decidua,
downregulate cytolytic activity, whereas Th1 cytokines (IL-
2, IL-15, IL-12, and IL-18) upregulate the same. In case
of activation, the interaction between target and eﬀector
cells results in eﬀector cell activation and directed granule
exocytosis (IA). In case of hyperactivation of NK cells, that is,
stimulation of IL-2, granulysin is released from cytoplasmic
granules of NK cells and accumulates in the cytoplasm and
nuclei of EVT cells in spontaneous abortions (IB). The
ligation of FasL, expressed on NK or T-cell surface, with
the death receptor Fas, on the target cell, results in caspase
cascade activation (IC). All pathways result in endonuclease
activation and apoptosis. At the same time, high granulysin
levels might have a protective role at the maternal-fetal inter-
face by (i) contributing to the local innate immune capacity
against intracellular and extracellular pathogens (II), or (ii)
acting as an immunomodulatory molecule by inducing phe-
notypical and functional maturation of dendritic cells, and
(iii) as a proinflammatory molecule by inducing chemotaxis
of diﬀerent immune cells and upregulating the adaptive
immune response (III).
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